APA

Kleeberg U. R., Suciu S., Bröcker E. B., Ruiter D. J., Chartier C., Liénard D., Marsden J., Schadendorf D. & Eggermont A. M. M. (20040227). Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. : European journal of cancer (Oxford, England : 1990).

Chicago

Kleeberg U R, Suciu S, Bröcker E B, Ruiter D J, Chartier C, Liénard D, Marsden J, Schadendorf D and Eggermont A M M. 20040227. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. : European journal of cancer (Oxford, England : 1990).

Harvard

Kleeberg U. R., Suciu S., Bröcker E. B., Ruiter D. J., Chartier C., Liénard D., Marsden J., Schadendorf D. and Eggermont A. M. M. (20040227). Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. : European journal of cancer (Oxford, England : 1990).

MLA

Kleeberg U R, Suciu S, Bröcker E B, Ruiter D J, Chartier C, Liénard D, Marsden J, Schadendorf D and Eggermont A M M. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. : European journal of cancer (Oxford, England : 1990). 20040227.